Ke Ma

Air Force Medical University

H指数:16

被引数:1,362

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nitric-oxide propelled nanomotors sensitize tumors to ferroptosis immunotherapy via cholesterol depletion-induced tumor cells stiffening

一氧化氮推进的纳米马达通过胆固醇耗竭诱导的肿瘤细胞硬化来增强肿瘤对铁死亡免疫治疗的敏感性

Materials Today Bio

IF10.2

2026-08-010

PRE

Development of hyaluronic acid-modified pH-responsive Cu-based nanocascade reactor for enhanced cancer chemo-chemodynamic synergistic therapy

透明质酸修饰的pH响应性铜基纳米级联反应器的开发，用于增强癌症化疗-化学动力学协同疗法

Colloids and Surfaces B: Biointerfaces

IF5.6

2026-03-160

PRE

Serum peptidomics profiling reveals fibrinogen alpha chain-derived peptides associated with clinical outcome in patients with heart failure

血清肽组学分析揭示了与心力衰竭患者临床结局相关的纤维蛋白原α链衍生的肽段

BMC CARDIOVASCULAR DISORDERS

IF2.3

2025-11-170

OAAI

Association between brain-gut peptides and depression: A systematic review and meta-analysis

脑-肠肽与抑郁症之间的关联：一项系统评价和荟萃分析

Psychoneuroendocrinology

IF3.6

2025-06-270

PRE

Optogenetic vagal nerve stimulation attenuates heart failure by limiting the generation of monocyte-derived inflammatory CCRL2+ macrophages

光遗传迷走神经刺激通过限制单核细胞来源的CCRL2+巨噬细胞的生成来减轻心力衰竭

Immunity

IF26.3

2025-06-270

PRE

Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels

JOURNAL OF THE AMERICAN HEART ASSOCIATION

IF5.3

2025-02-040

OAAI

Derivation and external validation of mass spectrometry-based proteomic model using machine learning algorithms to predict plaque rupture in patients with acute coronary syndrome

CLINICA CHIMICA ACTA

IF2.9

2024-09-010

OAAI

Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-05-061

OAAI

S100A8/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure

NATURE COMMUNICATIONS

IF15.7

2024-03-276

OAAI

ATF3 coordinates the survival and proliferation of cardiac macrophages and protects against ischemia-reperfusion injury

cardiovascular research

IF10.8

2024-01-043

OAAI

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism

JOURNAL OF CLINICAL MEDICINE

IF2.9

2022-07-053

OAAI

Therapeutic and Prognostic Significance of Arachidonic Acid in Heart Failure

CIRCULATION RESEARCH

IF16.2

2022-04-0122

OPG/TRAIL ratio as a predictive biomarker of mortality in patients with type A acute aortic dissection

OPG/TRAIL比值作为a型急性主动脉夹层患者死亡率的预测生物标志物

NATURE COMMUNICATIONS

IF15.7

2021-06-078

OAAI

Circulating miRNAs Related to Long-term Adverse Cardiovascular Events in STEMI Patients: A Nested Case-Control Study

CANADIAN JOURNAL OF CARDIOLOGY

IF5.3

2021-01-0120

OAAI

mir15a/mir16-1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2020-12-158

OAAI

Diabetic retinopathy in China: population-based studies and clinical and experimental investigations

LANCET

IF88.5

2017-12-012

OAAI

Ocular hypertension

ACTA OPHTHALMOLOGICA

IF2.8

2013-05-290

OAAI

10-Year Incidence and Associations of Pterygium in Adult Chinese: The Beijing Eye Study

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

IF4.7

2013-02-2727

OAAI

Effect of intravitreal cell-based produced glucagon-like peptide-1 on Bcl and BAX expression in the optic nerve crush model

ACTA OPHTHALMOLOGICA

IF2.8

2011-12-092

OAAI

Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model

在视神经挤压模型中玻璃体内基于细胞的胰高血糖素样肽-1产生的神经保护作用

ACTA OPHTHALMOLOGICA

IF2.8

2011-04-0628

PREAI

Ke Ma

个人简介

教育背景

工作经历

荣誉奖项

研究方向